The optics may not be good, but the health economics of it would...

The optics may not be good, but the health economics of it would suggest a possible reimbursement of >USD100,000, which for AUD purposes would approach 200k.Back of the envelope, one would have to calculate the decrease in ICU days multiplied by the cost per day of ICU stay. This would be the minimum in considering reimbursement, and there would be other factors. I only know what's coming out in the media, but it would appear that once on ventilation (the demographic MSB is looking at, i.e. the sickest of the sick) it's either death, a prolonged ICU stay, or both. The anecdotal evidence this far is that improvement with remestemscel is seen within days. This https://ccforum.biomedcentral.com/articles/10.1186/s13054-017-1689-y refers to Canada and I would hazard a guess that USA would be more expensive, but it would appear that we're talking about $10,000 per day at a minimum. That's my back of the envelope calculation and doesn't consider improvements in overall QALY. The biggest stumbling block would be optics. Even I can appreciate that $100-200k to save lives in the worst pandemic in a century would look suboptimal, despite me being a shareholder. Anyway DYOR, I'm just a random taking a punt like everyone else.